

Top Stories This Week

- DoT Exempts Short Range Microphones & Radars From Licensing: PTI sources
- ADB Revises India Forecast of GDP Growth For FY16 At 7.4% Vs March Estimate Of 7.8% On Weak Demand & Reform Delays
- MMTC Board Approves Proposal For Sale Of 10% ICEX Equity To 2 Bidders.
- Airtel to bill pre-paid users per second to rein in on call drops.
- SEBI Imposes Penalty Of `7,269 Cr On PACL & 4 Dirs For Illegal Money Mobilisation.
- REC inks 2 MoUs with Andhra utilities to provide Rs 9,000 crore loan.
- Glenmark launches Teneligliptin in Pune (oral anti-diabetic agent, used for diabetes mellitus management)
- Hotel Leela venture sells The Leela Goa to Malaysian firm MetTube for Rs 725 crore.
- Aurobindo Pharma gets US FDA nod for cholesterol drug Gemfibrozil.
- SPARC Files Draft Offer Letter For `250 Cr Rights Issue.
- Aditya Birla Chemicals (India) has completed the acquisition of the Chlor-Alkali Division of Jayshree Chemicals.

Weekly Indices Change

Index	Close	Prev Close	Chg. (%)
SENSEX	25863	26218	-1.35
NIFTY	7868	7981	-1.42
MIDCAP	10597	10646	-0.46
SMLCAP	10942	10804	1.28
METAL	6887	7291	-5.54
OIL&GAS	8635	8750	-1.31
AUTO	17316	17571	-1.45
TECK	6210	6137	1.19
BANKEX	19696	19952	-1.28
IT	11472	11229	2.16
FMCG	7573	7588	-0.20
HC	17616	17438	1.02
PSU	6644	6788	-2.12
CD	10499	10153	3.41
POWER	1808	1847	-2.11
CG	15058	15567	-3.27
REALTY	1328	1330	-0.15

Global Indices

DOW	16314	16384	-0.43
NASDAQ	4686	4827	-2.92
FTSE	6109	6104	0.08
NIKKEI	17880	18070	-1.05
HANGSENG	21186	21920	-3.35


Top Gainers Weekly

Scrip	Price	% Chg
IDBI Bank Ltd.	27.97	27.97
Nandan Denim	138.60	22.82
Granules India Ltd	141.45	20.64
V2 Retail	70.95	20.46
Dishman Pharma	302.25	18.83

Top Losers Weekly

Scrip	Price	% Chg
SKS Microfinance	392.65	15.74
Tata Motors Ltd.	303.40	12.51
Bharat Forge	903.05	12.00
JSW Steel	880.30	11.37
Tata Steel	215.15	11.02

Nifty Corner



Support & Resistance						
S3	S2	S1	Nifty	R1	R2	R3
7650	7700	7800	7868	7950	8050	8100
Moving Averages						
20DMA		50DMA		100DMA		200DMA
8295		8395		8345		8445

Market Commentary

A more than 2% slide on Tuesday, 22 September 2015, resulted in weekly losses for key benchmark indices. The sharp slide for Indian stocks on 22 September 2015 materialized as European stocks tumbled and as US index futures fell sharply after the scandal surrounding emissions-test cheating at Germany car major Volkswagen AG deepened. The barometer index, the S&P BSE Sensex fell below the psychological 26,000 level. The Sensex and the 50-unit CNX Nifty declined in two trading sessions and registered gains in two sessions during the week ended Thursday, 24 September 2015. For the next week Nifty likely to trade in the range between 7950 - 8050 in the upper side and 7800 – 7700 in the lower side.

Stocks at 52 wk High

Scrip	Cmp
Cadila Health	2038.80
Ceat	1273.55
Dishman Pharma	302.25
Jubilant Life	379.90
Mindtree	1560.30

Stocks at 52 wk Low

Scrip	Cmp
Bharti Airtel	332.95
BHEL	198.15
Coal India	318.40
Hindalco	71.40
Tata Motors	303.40

FII Activity

Date	Figures in crore
21/09	154.87
22/09	-1052.24
23/09	-1330.12
24/09	-115.10
25/09	--
NET	-2342.59

DII Activity

Date	Figures in crore
21/09	104.08
22/09	378.26
23/09	891.36
24/09	50.67
25/09	--
NET	1424.37

Weekly Stock Idea

Scrip	B/S	Cmp	Tgt
PTC	B	56	68
EXIDEIND	B	159	174
CROMPGREAV	B	175	192
OBEROIRTLY	B	262	288
GSPL	B	117	124

Buy on dips & Sell on rise with Stop-loss of 3%

Volume Breakout Stocks

Scrip	Cmp
Elder Pharma	113.55
PTC India	55.95
Can Fin Homes	874.25
V2 Retail	70.95
TV18 Broadcast	34.85

Week Ahead

MAJOR RESULTS/AGM MEETING THIS WEEK:

28 SEP: NAMASTEXP

[VISIT US AT: WWW.INDIRATRADE.COM](http://WWW.INDIRATRADE.COM)

Disclaimer

This report is for private circulation within the Indira Group. This report is strictly confidential and for information of the selected recipient only and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form. This report should not be construed as an offer or solicitation to buy or sell any securities or any interest in securities. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or any such factor. The information, opinions estimates and forecasts contained here have been obtained from, or are based upon, sources we believe to be reliable, but no representation of warranty, express or implied, is made by us to their accuracy or completeness. Opinions expressed are our current opinions as of the date appearing on this material only and are subject to change without notice.